At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Jun 22, 2026 at 07:00 ET
NRx Pharmaceuticals announced FDA approval of an Expanded Access Protocol for NRX-101 (D-cycloserine/lurasidone) to augment Transcranial Magnetic Stimulation (TMS) in patients with Treatment-Resistant Depression. The company will initially charge only for shipping and data collection costs, not for the investigational drug, while a pivotal trial (SPARC-TMS) is underway. This is a procedural regulatory step that provides compassionate access but does not change the drug's approval status or provide new efficacy data.
- FDA approved an Intermediate Population Expanded Access Protocol for NRX-101 to augment accelerated TMS in Treatment-Resistant Depression.
- NRX-101 is a fixed-dose combination of D-cycloserine and lurasidone, with Breakthrough Therapy Designation for suicidal bipolar depression.
- Company will initially charge only for shipping and FDA-required data collection costs, not for the investigational drug.
- Pivotal trial SPARC-TMS is ongoing in civilian and military treatment facilities.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access